Analysis of NUP98/NSD1 translocations in adult AML and MDS patients
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The Nucleoporin 98 (NUP98) gene has received a significant amount of interest in hematology because of the discovery of numerous NUP98 gene fusions in hematopoetic malignancies, with at least 28 reported fusion partner genes. 1 Together with B50 other proteins, the NUP98 protein belongs to the nuclear pore complex (NPC). In addition to its role within the NPC, NUP98 has been found to be involved in gene transcription, cell cycle progression and mitotic spindle formation. 1 Thus, NUP98 has very different roles in cell homeostasis.
Recently, a specific fusion of NUP98 with nuclear receptorbinding SET domain protein 1 (NSD1), which is cytogenetically cryptic, has been analyzed in a large cohort of pediatric and adult acute myeloid leukemic (AML) patients.
2 NSD1 belongs to a large family of histone methyltransferases that are capable of both negatively and positively influencing transcription. 3 In the paper by Hollink et al., 2 16.1% of pediatric cytogentically normal (CN)-AML samples and 2.3% of adult CN-AML cases were found to be NUP98/NSD1 positive. These patients showed a higher white blood cell (WBC) count, were more frequently classified as FAB M4/M5, were more likely to have a internal tandem duplication (ITD) of the FLT3 gene (FLT3-ITD) or a WT1 mutation and showed a distinct Hox gene expression pattern. Interestingly, NUP98/NSD1-positive patients were found to have a worse prognosis compared with NUP98/NSD1-negative patients. As the study by Hollink et al. 2 has been the first systematic analysis of NUP98/NSD1 in a large AML cohort, we aimed at investigating the frequency, clinical features and the prognostic impact of NUP98/ NSD1 in another large, uniformily treated adult AML cohort, as well as in patients with myelodysplastic syndromes (MDS), which frequently precede overt leukemia.
We examined 504 younger adult AML patients (o60 years) and 193 MDS patients for the presence of NUP98/NSD1 translocations. All AML patients were treated within the multicenter treatment trials AML SHG 0295 or AML SHG 0199, as previously reported. 4 A total of 193 MDS patients were examined, who were enrolled in clinical trials as previously described. 5 Pretreatment samples from all patients were studied centrally by G-and R-banding analysis. Chromosomal abnormalities were described according to the International System for Human Cytogenetic Nomenclature. Analysis in the AML cohort was also performed for mutations in FLT3-ITD, NPM1, DNMT3A, IDH1 and IDH2. 6 Additional mutation
Accepted article preview online 29 August 2012; advance online publication, 14 September 2012 Letters to the Editor analyses were performed in the subgroup of CN-AML for CEBPA, MLL-PTD, WT1 and WT1 SNP rs16754, NRAS and expression levels of BAALC, ERG, EVI1, MN1, MLL5 and WT1 as previously described. 7 Mutation analyses of MDS samples were performed for ASXL1, DNMT3A, IDH1, IDH2, RUNX1, NRAS, TP53, NPM1, SF3B1, SRSF2, U2AF1 and ZRSR2 as previously reported. 8 Written informed consent was obtained according to the Declaration of Helsinki, and the study was approved by the institutional review board of Hannover Medical School.
Preparation of mononuclear cells and analysis of prognostic markers were performed as previously reported. 6 Reverse transcriptase (RT) À PCRs using patient-derived complementary DNA (cDNA) were accomplished on a MyCycler Thermal Cycler (Bio-Rad, Munich, Germany). All reactions were carried out in duplicate. Sequences of the outer primers were as follows: forward 5 -TGGACAGGCATCTTTGTT-3 and reverse 5 -ACAGCGGGAACTTA CCTT-3 . Sequences of the inner primers were as follows: forward 5 -TAAGATTGGAGGGCCTCTTG-3 and reverse 5 -GCACCTGCTCCT The cytogenetic risk group is defined according to the MRC criteria. 15 GTACCTTC-3 . cDNA from a patient with proven NUP98/NSD1 fusion was used as a positive control. 2 Positive patients were independently validated by RT À PCR.
Mutations and polymorphisms in the analyzed genes were used as categorical variables. Pairwise comparisons of variables for exploratory purposes were performed using the Kolmogorov À Smirnov test and Student's t-test for continuous variables and the w 2 test for categorical variables. For AML, the definition of complete remission (CR), overall survival (OS) and relapse-free survival (RFS) followed recommended criteria. 9 Median follow-up time for survival was calculated according to the method of Korn. 10 OS end points, measured from the date of entry into one of the prospective studies, were death (failure) and alive at the last follow-up (censored). RFS end points, measured from the date of documented CR, were relapse (failure), death in CR (failure) and alive in CR at the last follow-up (censored). The Kaplan À Meier method and log-rank test were used to estimate the distribution of OS and RFS and to compare differences between survival curves, respectively. To provide quantitative information on the relevance of results, 95% confidence intervals (CIs) of odds ratios and hazard ratios (HR) were computed. Two-sided P values o0.05 were considered significant in the primary analysis, and as NUP98/NSD1 fusions were identified in 7 out of 504 younger adult AML patients (1.4%), in line with a previous report, which found a significantly higher incidence of NUP98/NSD1 fusions in pediatric compared with adult AML patients. 2 Thus, it is not surprising that NUP98/NSD1-positive AML patients were younger compared with NUP98/NSD1-negative AML patients in our cohort (median age 34 vs 46 years, P ¼ 0.086, Table 1 ).
None of the 193 MDS patients was found to show the NUP98/ NSD1 fusion, suggesting that the NUP98/NSD1 fusion does not have a role in the pathogenesis in MDS, whereas other NUP98 fusions have been reported to occur in MDS, such as NUP98/ PSIP1 11 or NUP98/NSD3.
12
In our AML cohort, NUP98/NSD1-positive patients showed a higher number of peripheral blood blasts (P ¼ 0.002, Table 1 ), whereas other clinical characteristics such as the FAB subtype, type of AML, hemoglobin levels and WBC or platelet count did not significantly differ between patients with or without the NUP98/ NSD1 fusion ( Table 1 ). The majority of NUP98/NSD1-positive patients (five out of seven) showed a normal karyotype, whereas one patient was found to have a karyotype with del(9q) and another patient an inv(3)(q21q26) karyotype with monosomy 7. Our analysis included a comprehensive mutational analysis that allowed us to perform a detailed assessment for possible associations between mutations and the NUP98/NSD1 fusion. We identified an association between FLT3-ITD and NUP98/NSD1 fusion in our cohort (P ¼ 0.007, Table 1 ). This finding confirms the data by Hollink et al., 2 and suggests a possible functional link between FLT3-ITD and NUP98/NSD1 fusion in leukemogenesis. NUP98 fusions have previously been described as aberrations that primarily block differentiation (type II mutation according to Gilliland 13 ), whereas FLT3-ITD are classified as aberrations that cause uncontrolled proliferation (type I mutation).
13 NUP98/NSD1 fusions were not associated with other mutations such as those suggested in epigenetic regulation (DNMT3A, IDH1 and IDH2, Table 1 ). In CN-AML, we also looked for an association between BAALC, ERG, EVI1, MN1, MLL5 and WT1 expression, but could not find a significant difference between the expression of these genes and NUP98/NSD1 fusion genes (data not shown).
In our AML cohort, we performed an outcome analysis comparing patients with or without the NUP98/NSD1 fusion. Owing to the low frequency of the aberration and the low patient number, this analysis is only for explorative purposes. Considering the whole AML cohort, we did not detect a significant difference for OS and RFS between NUP98/NSD1-positive and -negative patients (OS, HR 1.6; 95% CI 0.66 À 3.88; P ¼ 0.3; RFS, HR 2.33; 95% CI 0.74-7.30; P ¼ 0.147). However, NUP98/NSD1-positive patients had significantly lower CR rates (43% vs 77%, P ¼ 0.037). When considering only patients with CN-AML, the NUP98/NSD1-positive patients (n ¼ 5) had no significantly different OS and RFS (OS, HR 2.08; 95% CI 0.77-5.64; P ¼ 0.15, Figure 1c ; RFS, HR 2.88; 95% CI 0.71-11.71; P ¼ 0.14, Figure 1d ). Again, a significantly lower CR rate was achieved by the NUP98/NSD1-positive patients compared with NUP98/NSD1-negative patients with CN-AML (40% vs 80%, P ¼ 0.03). Owing to the association between FLT3-ITD and NUP98/NSD1, we also investigated the prognostic impact in the subgroup of CN-AML patients also positive for FLT3-ITD. Again, OS and RFS did not differ between NUP98/NSD1-positive and -negative patients (OS, HR 1.31; 95% CI 0.47-3.64; P ¼ 0.61, Figure 1e ; RFS, HR 2.04; 95% CI 0.49-8.57; P ¼ 0.33, Figure 1f ). For this subgroup, a trend toward a lower CR rate was observed for NUP98/NSD1-positive and FLT3-ITD-positive CN-AML patients (40% vs 75%, P ¼ 0.083). Functional studies on NUP98/NSD1 point to an important role in leukemogenesis. Overexpression of NUP98/NSD1 in mouse bone marrow caused AML after a median latency of 126 days by upregulation of HOXA cluster genes, most likely through interference with EZH2, a polycomb group gene involved in epigenetic regulation. 14 Our results show that NUP98/NSD1 fusions are rare in adult AML patients and are absent in MDS patients, suggesting that this fusion is rather specific for childhood AML. In summary, our analysis confirms the presence but low incidence of the NUP98/ NSD1 fusion gene in adult AML patients and the association with FLT3-ITD and lower CR rates. The specific association of NUP98/ NSD1 with FLT3-ITD mutations warrants clinical investigation with FLT3 inhibitors in these patients.
Loss of CD44 attenuates aberrant GM-CSF signaling in Kras G12D hematopoietic progenitor/precursor cells and prolongs the survival of diseased animals CD44 is a transmembrane glycoprotein expressed on the surface of many cell types including the majority of myeloid cells and early thymic T-cell progenitors. 1 As a cell adhesion molecule, CD44 is differentially required for the adhesion and mobility of different leukemia-initiating cells. In animal models of BCR-ABL-induced human hematopoietic malignancies, CD44 is required for the homing and engraftment of chronic myeloid leukemia-initiating cells, but is dispensable for the engraftment of B-cell lymphoblastic leukemia-initiating cells. 2 In contrast, in an animal model of human acute myeloid leukemia, a CD44-activating antibody eradicates leukemia-initiating cells partially by interfering with their interaction with the microenvironment.
3 CD44 is also an important regulator of cell signaling and regulates signaling cascades in various ways. 1 For example, CD44 can provide specialized platforms for growth factors and matrix metalloproteinases, act as a coreceptor in many receptor complexes and/or organize signaling cascades through association with cytoskeleton.
During tumorigenesis, various signals have been implicated in regulating CD44 expression and/or its alternative splicing. A positive-feedback loop has been identified to couple the activation of Ras/ERK signaling and induction of CD44 expression, in particular expression of its splicing variant v6. 4 Ras signaling promotes CD44v6 expression, and in turn CD44v6 sustains late Ras signaling. Consistent with this finding, we and others previously reported that CD44 is invariably overexpressed in T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) induced by endogenous oncogenic Kras (Kras G12D) or oncogenic Nras. [5] [6] [7] Under physiological conditions, CD44 is only transiently expressed in early thymic T-cell progenitors at the CD4, CD8-double negative 1 (DN1) and DN2 stages. However, in T-ALL patients, CD44 is often expressed in the tumor T cells. Expression of CD44 correlates with increased numbers of circulating blasts, as well as tissue infiltration, 8 and is a negative prognostic factor. 9 Activation of CD44 enhances DNA repair and thus protects T-ALL cells from chemo/radiation therapy-induced apoptosis. Consistent with this finding, blocking of the CD44 function by IM7 antibody sensitizes T-ALL cells to dexamethasoneinduced apoptosis. Despite the apparently necessary role of CD44 in some types of cancers, CD44 is dispensable in normal cells as mice develop and survive well in the absence of CD44. 10 This makes CD44 an attractive target for treating CD44 þ cancers. Given the important role of CD44 in homing and engraftment of tumor cells, as well as in modulating cytokine signaling, we asked whether and how CD44 deficiency affects Kras G12D-induced hematopoietic malignancies. To address these questions, we generated LSL Kras G12D/ þ ; Mx1-Cre mice and LSL Kras G12D/ þ ; Mx1-Cre; CD44
À / À mice ( Figure S1A ). Administration of polyinosinic-polycytidylic acid (pI-pC) in these compound mice induces expression of Kras G12D. We refer to these pI-pC-treated compound mice as Kras G12D and Kras G12D; CD44 À / À mice, respectively, and pI-pC-treated Mx1-Cre or wild-type mice as control mice throughout this paper.
After acute induction of Kras G12D expression in whole bone marrow cells, both Kras G12D and Kras G12D; CD44 À / À mice showed marked splenomegaly, which is characteristic of myeloproliferative neoplasm (MPN) (Figure 1a and Figure S1B ). However, the average spleen weight of Kras G12D; CD44 À / À mice was significantly lower than that of Kras G12D mice, suggesting that CD44 deficiency attenuates but does not completely prevent acute MPN development in Kras G12D mice. Consistent with this finding, Kras G12D; CD44 À / À mice indeed survived significantly longer than Kras G12D mice (Figure 1b) . At the moribund stage, these two groups of mice showed comparable MPN phenotypes ( Figure S2 ).
To investigate whether the diminished MPN phenotypes observed in Kras G12D; CD44 À / À mice are owing to reduced cytokine signaling, we analyzed granulocyte-macrophage colonyforming factor (GM-CSF)-and interleukin-3 (IL-3)-evoked ERK1/2 and STAT5 activation in both c-Kit þ Lin À /low cells (R1, enriched for myeloid progenitors) and c-Kit À Lin À /low cells (R2, enriched for myeloid precursors), 11 as well as stem cell factor (SCF)-evoked AKT activation in R1 cells. Our results show that CD44 deficiency greatly attenuates aberrant GM-CSF signaling in Kras G12D myeloid progenitor/precursor cells, while it has no significant effect on IL-3-and SCF-evoked signaling in Kras G12D cells (Figure 1c and Figure S3 ). Together, these results demonstrate that CD44 deficiency compromises some but not all of the cytokine signaling in Kras G12D cells, which might contribute to the moderate attenuation of MPN phenotypes in Kras G12D; CD44 À / À mice. In a bone marrow transplantation model, mice receiving Kras G12D cells develop a highly penetrant T-ALL with a low incidence of MPN. The possible reasons leading to this drastic phenotypic switch are extensively discussed in previous publications. 6, 12 We found that only Kras G12D hematopoietic stem cells (HSCs), but not other lineage-committed progenitors, initiate both MPN 6 and T-ALL in recipient mice (Table S1 ), indicating that in Kras G12D model, genetically altered HSCs are the cell origin for both MPN and T-ALL. Therefore, we next determined whether loss of CD44 affects the properties of Kras G12D HSCs. Surprisingly, CD44 is dispensable in Kras G12D HSCs. CD44 deficiency did not affect the Accepted article preview online 31 August 2012; advance online publication, 14 September 2012
